Industry Tutorial: Powering the Age of Immune Medicine to Advance Differentiated Diagnostics and Therapeutics in Autoimmunity and Transplantation

Thursday, June 23, 2022

11:30 AM – 12:45 PM PT

Location: Salons 3/4

Sponsored By

Speaker(s)

Jianing Fu, PhD

Instructor
Columbia University
New York, New York, United States
Catherine Sanders, Ph.D.

Vice President, Business Development
Adaptive Biotechnologies
Seattle, Washington, United States
Harlan Robins, PhD

Chief Scientific Officer
Adaptive Biotechnologies
Yarrow Point, Washington, United States

In this presentation:

• Overview of Adaptive Biotechnologies’ immunosequencing and immune medicine platforms.
• Development of autoimmune diagnostics and therapeutics leveraging Adaptive's immunosequencing and drug discovery platforms.
• Using the immunoSEQ assay and T MAP COVID Search Tool to gain insights into TCR repertoire dynamics and HLA restriction in solid organ transplant recipients with COVID-19 infection.

For Research Use Only. Not for use in diagnostic procedures.

Program Agenda:
11:30 am Introduction to Adaptive and Technology
CATHERINE SANDERS, MT, Ph.D.
VP, Research and Business Development,
Adaptive Biotechnologies

11:50 amDevelopment of Autoimmune Diagnostics and Therapeutics
HARLAN ROBINS, Ph.D.
Chief Scientific Officer and Co-Founder,
Adaptive Biotechnologies

12:10 pm HLA Restriction of T-cell Antigen Recognition of Sars-Cov2 and Application of HLA Classifier Algorithm in Human Solid Organ Transplantation Settings
JIANING FU, Ph.D.
Columbia University Irving Medical Center (CUIMC),
Columbia Center for Translational Immunology (CCTI)
Department of Medicine

12:30 pm Summary and Q&A
Moderator: CATHERINE SANDERS, MT, Ph.D.

Learning Objectives:

Overview of Adaptive Biotechnologies’ immunosequencing and immune medicine platforms
Development of autoimmune diagnostics and therapeutics leveraging Adaptive's immunosequencing and drug discovery platforms
Using the immunoSEQ assay and T MAP COVID Search Tool to gain insights into TCR repertoire dynamics and HLA restriction in solid organ transplant recipients with COVID-19 infection